Barinthus Biotherapeutics will merge with Clywedog Therapeutics, a privately held company specializing in diabetes medicines, in an all-stock transaction. The immunology and inflammation company said ...

GERMANTOWN, MD and ALTRINCHAM, UK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- GERMANTOWN, MD and ALTRINCHAM, UK — September 30, 2025 — Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio”), an ...

CLYWEDOG reservoir has gained the reputation for being the best value-for-money fishery in the whole of the UK. CLYWEDOG reservoir has gained the reputation for being the best value-for-money fishery ...

Barinthus Biotherapeutics (BRNS) announced on Tuesday that it will merge with Clywedog Therapeutics in an all-stock transaction. Following the announcement, the company's shares slid 4% in the ...

GERMANTOWN, Md. and ALTRINCHAM, United Kingdom, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio”), an immunology and inflammation company focused on ...

Clywedog’s approach for Type 1 diabetes also provides the potential to pursue a multi-component regimen, synergistically combining its assets to first prevent or slow inflammation and then stimulate ...

The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates which are being studied for the prevention/reversal of Type 1 ...

The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates which are being studied for the prevention/reversal of Type 1 ...